Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Announces Publication of Research Demonstrating the Impact of the Novel Treatment, Arina-1 on Mucus Transport in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Mitsubishi Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Corporation Life Sciences Granted New US Patent for \"Composition Containing Glutathione as an Active Ingredient for Improvement or Prevention of Non-Alcoholic Fatty Liver\"","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of Non-CF Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Marizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3101

    Menu

    DSSTox_CID_3101

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Renovion

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis

              Details:

              ARINA-1 is a new nebulized product comprised of ascorbic acid, glutathione, and bicarbonate which is currently being investigated in phase 2 clinical trials for the treatment of patients with Non-cystic Fibrosis Bronchiectasis.

              Lead Product(s): Ascorbic Acid,Glutathione,Bicarbonate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Arina-1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Marizyme

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™

              Details:

              DuraGraft is a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.

              Lead Product(s): Glutathione,Ascorbic Acid

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: DuraGraft

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Renovion

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

              Details:

              ARINA-1 (ascorbic acid) is an investigational nebulized therapy to prevent the progression of bronchiolitis obliterans syndrome (BOS) progression in individuals with a bilateral lung transplant.

              Lead Product(s): Ascorbic Acid,Glutathione

              Therapeutic Area: Immunology Product Name: ARINA-1

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Renovion

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Renovion Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of Non-CF Bronchiectasis

              Details:

              ARINA-1 (ascorbic acid), an investigational nebulized therapy, to treat adults with non-CF bronchiectasis,has been shown to have significant mucolytic activity, as well as robust anti-inflammatory properties.

              Lead Product(s): Ascorbic Acid,Glutathione

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mitsubishi Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mitsubishi Corporation Life Sciences Granted New US Patent for "Composition Containing Glutathione as an Active Ingredient for Improvement or Prevention of Non-Alcoholic Fa...

              Details:

              USPTO has granted a patent to Mitsubishi Corporation Life Sciences for a method of improving nonalcoholic fatty liver disease in patients in need of treatment, comprising the administration of a composition containing glutathione as its active ingredient.

              Lead Product(s): Glutathione

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Opitac

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Renovion

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Renovion Announces Publication of Research Demonstrating the Impact of the Novel Treatment, Arina-1 on Mucus Transport in Cystic Fibrosis

              Details:

              The paper provides an overview of the impact of ARINA-1 on mucus transport and shows that the ARINA-1 moves mucus significantly better than currently available options in cystic fibrosis (CF).

              Lead Product(s): Ascorbic Acid,Glutathione,Bicarbonate

              Therapeutic Area: Genetic Disease Product Name: ARINA-1

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY